Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,047

Document Document Title
WO/2022/166369A1
Disclosed is a crystal form A of a compound. The compound is S-(-)-2,3-methylenedioxy-5,8,13,13a-tetrahydro-10,11-dimetho xy-6H- dibenzo[a,g]quinolizine, and the X-ray powder diffraction pattern of the crystal form A comprises three or m...  
WO/2022/161468A1
The invention provides pharmaceutical compositions of berberine ursodeoxycholate (BUDCA) and methods of use thereof for the treatment primary sclerosing cholangitis, and related diseases and conditions.  
WO/2022/120209A1
Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Compound I dihydrochloride. Also provided are processes of manufacture and methods of using the crystalline for...  
WO/2022/099374A1
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.  
WO/2022/095972A1
The present invention relates to an application of an isoquinoline compound in tumor treatment. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer or a racemate thereof, or a solvate there...  
WO/2022/057906A1
Disclosed are a compound for preventing and treating liver diseases and the pharmaceutical use thereof, which belong to the field of medical technology. Specifically disclosed is a compound as represented by formula I-1, or a pharmaceuti...  
WO/2022/012693A1
The present invention relates to a codrug that disintegrates in the intestine, preparation therefor, and a use thereof. Specifically, provided is a codrug compound in formula I. Also provided are a method of using the present compound fo...  
WO/2021/212691A1
A mitochondria targeting compound, a preparation method therefor and use thereof. The structure of the mitochondria targeting compound is as shown in formula I or formula II, wherein R1 and R2 are each independently selected from hydroge...  
WO/2021/189112A1
A method for detection of a nerve agent in a sample, which method comprises (a) irradiating an optical sensing element, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, and measuring the lumi...  
WO/2021/169658A1
Disclosed are a small molecule fluorescent probe and application thereof in chromosome analysis and cytogenetics. The present invention can be used as a multi-purpose tool for chromosome image segmentation to identify overlapping, cluste...  
WO/2021/168561A1
The present invention provides solvent-limited processes for the preparation of an existing crystalline solid form of an active pharmaceutical ingredient comprising mixing, in the presence of solvent vapour, of a solid active pharmaceuti...  
WO/2021/141969A1
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...  
WO/2021/129720A1
Disclosed are a columbamine preparation method and a columbamine. The preparation method comprises: taking berberine hydrochloride, adding xylene and trichloroacetic acid to the berberine hydrochloride for reaction at a first predetermin...  
WO/2021/129783A1
Disclosed are a preparation method for and an application of demethyleneberberine. The preparation method comprises the following steps: adding berberine hydrochloride to xylene, then adding trifluoromethanesulfonic acid, stirring at roo...  
WO/2021/106975A1
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. A compound represented by formula (I) (in the formula, each symbol is as described in the specification) or a salt thereof has orexi...  
WO/2021/098737A1
The present invention falls within the medical field, and specifically relates to a fused heterocyclic derivative and a use thereof. The fused heterocyclic derivative has the structure of a compound as shown in formula (I), wherein the c...  
WO/2021/067490A1
The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatoh...  
WO/2021/059136A1
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2021/050977A1
The present application relates to processes for making (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahyd ro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of...  
WO/2021/050473A1
The present disclosure relates to antimicrobial compositions, particularly to antibiotic compositions; to methods for identification of antimicrobial compositions involving in silico prediction of antimicrobial activity; and to use of an...  
WO/2021/046194A1
The present inventions relates to tryptoline-based benzothi azole compounds and their use as both novel resistance modifying agents, and antibiotics.  
WO/2021/027792A1
The present invention relates to a class of compounds that serve as VMAT2 inhibitors, and relates in particular to a compound represented by formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof, and a preparation me...  
WO/2020/234272A1
The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5- trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10 ,10a- octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-car boxylic acid with th...  
WO/2020/234275A1
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...  
WO/2020/234271A1
The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5- trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10 ,10a- octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-car boxylic acid with the fo...  
WO/2020/234274A1
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...  
WO/2020/221217A1
A fluorescent dye, a preparation method therefor, and a use thereof; the fluorescent dye is sensitive and specific to viscosity response, has the advantage of low background fluorescence, and can be used as a fluorescence activated dot l...  
WO/2020/177744A1
Disclosed in the present invention are a salicylic acid berberine-type alkaloid quaternary ammonium compound as shown in general formula (I), a preparation method therefor, solubility characteristics, a pharmaceutical composition and an ...  
WO/2020/143604A1
The present invention provides a dihydroisoquinoline compound or a pharmaceutically acceptable salt, ester, isomer, solvate, hydrate, prodrug, or isotopic label thereof, having the structure of a compound of general formula I: (I). The c...  
WO/2020/122092A1
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. A compound represented by formula (I) [in the formula, each symbol is as described in the description] or a salt thereof has orexin ...  
WO/2020/108330A1
The present disclosure relates to crystalline salt forms of the following Compound (1), also known as l-corydalmine or l-CDL, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in methods for the ...  
WO/2019/196955A1
Disclosed are an 8-dihalide methyl berberine quaternary ammonium compound shown in formulas (I) and (II), a synthetic method therefor, and an application thereof in preparation of drugs. The 8-dihalide methyl berberine quaternary ammoniu...  
WO/2019/174533A1
A small molecule PD-1/PD-L1 inhibitor and the use thereof in drugs. Specifically, provided is a small molecule PD-1/PD-L1 inhibitor that is a chemical compound represented by formula (I), or a stereoisomer, geometric isomer, tautomer, ox...  
WO/2019/166962A1
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated i...  
WO/2019/153644A1
Provided are four crystal forms, A, B, C and D, of demethylene berberine hydrochloride, and a preparation method therefor, and further provided are X‑ray powder diffraction characteristic absorption peaks, infrared absorption peaks and...  
WO/2019/150387A1
A novel process for preparation of Deutetrabenazine ((RR, SS)-l,3,4,6,7-llb-Hexahydro-9,10-di(methoxy-d6)-3-(2-methylp ropyl)-2H- benzo [a] quinolizin-2-one) of formula I comprises of methylation of N-(2-(3,4-dihydroxy-phenyl)-ethyl)-for...  
WO/2019/142555A1
The present invention provides a luminescent film containing at least a phosphorescent compound and a fluorescent compound, wherein the convolution integral value J of the emission spectrum of the phosphorescent compound and the absorpti...  
WO/2019/129681A1
The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2019/104141A1
Salts and solid state forms of Valbenazine, including Valbenazine ditosylate, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.  
WO/2019/074492A1
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H- pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically accep...  
WO/2019/034031A1
The present invention provides a tetrahydroprotoberberine compound represented by general formula (I), an enantiomer, a diastereoisomer and a raceme thereof and a mixture thereof, a pharmaceutically acceptable organic or inorganic salt t...  
WO/2019/023189A1
Methods for treating leukemia, e.g., acute myeloid leukemia (AML), using inhibitors of essential genes including decapping enzyme scavenger (DCPS).  
WO/2018/224016A1
Disclosed is the use of berberine or a derivative thereof in preparing a myocardial perfusion imaging agent, specifically the use of 18F-labelled berberine or a derivative thereof in preparing a myocardial perfusion imaging agent. In vit...  
WO/2018/219356A1
The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formu...  
WO/2018/222549A1
The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and f...  
WO/2018/205987A1
The invention generally relates to solid forms of berberine ursodeoxycholate, and to pharmaceutical compositions, and methods of preparation and therapeutic use thereof. In particular, the invention relates to solid forms of berberine ur...  
WO/2018/203302A1
This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of b...  
WO/2018/178251A1
The invention provides (+)-α-dihydrotetrabenazine succinate salt. Also provided are (+)-α-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-α-dihydrotetrabenazine succinate salt and a ...  
WO/2018/159849A1
Provided is: an azapyrene compound represented by general formula (1) [in the formula, R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or a cyano group, R2 represents a divalent hydrocarbon group having six or ...  
WO/2018/159662A1
A compound according to the present invention, which has a structure represented by general formula AA is useful as a light emitting material. In the general formula, at least one of R1-R9 represents a substituent; each of Y1-Y3 represen...  

Matches 1 - 50 out of 1,047